RYBREVANT amivantamab

Drug Class

Bispecific EGFR-MET antibody

Mechanism

Binds to extracellular domains of EGFR and MET, blocking ligand binding, promoting receptor downregulation, and inducing antibody-dependent cellular cytotoxicity (ADCC).

Approved Indication

EGFR exon 20 insertion mutation-positive advanced NSCLC, and EGFR exon 19 deletion or L858R substitution-positive advanced NSCLC (in combination with lazertinib), per its FDA approval.

What This Means For Patients

RYBREVANT is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2021) — Sources
• EMA — Approved (2021) — Sources

Pivotal Clinical Evidence

• CHRYSALIS — Park et al., J Clin Oncol 2021 (NCT02609776) — Sources

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-nsclc-egfr-exon-20-insertion-mutations
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf